Copy of Platform applications


 

SETTING A NEW STANDARD OF NEONATAL RESPIRATORY CARE
PREVENTATIVE CARE FROM THE FIRST BREATH

SCROLL DOWN

Copy of Platform applications


 

SETTING A NEW STANDARD OF NEONATAL RESPIRATORY CARE
PREVENTATIVE CARE FROM THE FIRST BREATH

 Transforming neonatal care with clinical AI

Within the first few hours after birth there is a short window of opportunity to protect newborns from severe and debilitating diseases, however, a lack of data often prevents doctors from delivering the necessary preventative treatment.

SIME has developed a unique new technology that has the intelligence required to deliver decisive data in the fast-paced environment of acute care. Pushing the boundaries of medical and data science, our technology provides doctors with the information they need to treat early, precisely and preventatively - even in the most fragile patients.

The first application of our patented and clinically proven technology is in the neonatal intensive care unit, where we are helping to prevent the leading cause of morbidity and mortality in premature babies – Respiratory Distress Syndrome.


Photo by annedehaas/iStock / Getty Images

Respiratory Distress Syndrome (RDS) is an urgent unmet clinical need

RDS, a breathing disorder caused by a lack of surfactant, it is the primary cause of mortality and severe morbidity in preterm babies. Today, a lack of data means that RDS can only be diagnosed with symptom onset hours after birth. Surfactant treatment is then administered, which slows, and eventually can halt, disease progression.  

RDS can be prevented with early treatment

Surfactant therapy is highly effective, and if administered minutes after birth it has the potential to prevent RDS. So why not give it to all babies? A COCHRANE REVIEW found that prophylactic treatment can harm healthy babies, therefore an early diagnostic for identifying which babies are at risk of RDS is needed. 


Our technology provides doctors with precise data minutes after birth

Requiring only a small sample of gastric aspirate, fluid routinely extracted from the stomach at birth, SIME can accurately predict RDS within minutes at the point-of-care. Enabling doctors to identify which babies are at risk of RDS and require preventative treatment. This is the first application of our neonatal and maternal health data engine.  


Scientifically proven, to predict RDS with HIGH sensitivity 

This lung maturity test has been developed to identify pre-term infants who will benefit from early surfactant treatment. By only rapidly intervening in those infants that need treatment, we can significantly improve RDS clinical outcomes, and potentially lessen the need for mechanical ventilation and oxygen.
— Henrik Verder, Christian Heiring, Howard Clark et al. ACTA Paediatrica 2016

Recent European Guidelines highlight the need for a bedside RDS test

Methods to measure the presence or absence of endogenous surfactant, such as lamellar body count in gastric aspirate, may help in deciding whom to treat. However, methods that require laboratory expertise around the clock are unlikely to be widely adopted and a simple bedside test that can be used within the NICU is needed.
— David G. Sweet et al. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update, Neonataology 2017;111:107-125.

The development of the neonatal lung maturity application is supported by EU Horizon 2020 Phase 2 SME Instrument (project no. 666668). 

Copy of Platform applications2


CLINICAL DATA ENGINE
APPLICATIONS IN THE NICU

NEW NEONATAL AND MATERNAL
HEALTH PRODUCTS IN DEVELOPMENT

Copy of Platform applications2


CLINICAL DATA ENGINE
APPLICATIONS IN THE NICU

NEW NEONATAL AND MATERNAL
HEALTH PRODUCTS IN DEVELOPMENT

More information coming soon.